腹水
卵巢癌
免疫疗法
癌症研究
免疫学
转移
免疫系统
生物
癌症
医学
内科学
作者
Karen Slattery,Cong-Hui Yao,Eimear Mylod,John Scanlan,Barry Scott,Joseph M. Crowley,Orla Mcgowan,Gavin McManus,Martin Brennan,Katie O’Brien,Kate Glennon,Edward Corry,Ann Treacy,Rafael J. Argüello,Clair M. Gardiner,Marcia C. Haigis,Donal J. Brennan,Lydia Lynch
出处
期刊:Science immunology
[American Association for the Advancement of Science]
日期:2025-05-09
卷期号:10 (107)
标识
DOI:10.1126/sciimmunol.adr4795
摘要
High-grade serous ovarian cancer (HGSOC) remains an urgent unmet clinical need, with more than 70% of patients presenting with metastatic disease. Many patients develop large volumes of ascites, which promotes metastasis and is associated with poor therapeutic response and survival. Immunotherapy trials have shown limited success, highlighting the need to better understand HGSOC immunology. Here, we analyzed cytotoxic lymphocytes [natural killer (NK), T, and innate T cells] from patients with HGSOC and observed widespread dysfunction across primary and metastatic sites. Although nutrient rich, ascites was immunosuppressive for all lymphocyte subsets. NK cell dysfunction was driven by uptake of polar lipids, with associated dysregulation in lipid storage. Phosphatidylcholine was a key immunosuppressive metabolite, disrupting NK cell membrane order and cytotoxicity. Blocking lipid uptake through SR-B1 protected NK cell antitumor functions in ascites. These findings offer insights into immune suppression in HGSOC and have important implications for the design of future immunotherapies.
科研通智能强力驱动
Strongly Powered by AbleSci AI